Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms

Otsuka Pharmaceutical has agreed to acquire Visterra for approximately $430 million cash, the companies said today, in a deal that expands the pipeline of Otsuka and aligns with its goal of enhancing its drug discovery and development platforms.Through the acquisition, Otsuka will inherit Visterra’s Hierotope ® platform, intended to design and engineer precision antibody-based therapies that specifically bind to, and modulate, disease targets not adequately addressed by current technol